1. Chen, Y.F., Jobanputra, P., Barton, P., et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. 10(42), 3–4 (2006)
2. Kvien, T.K.: Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22, 1–12 (2004)
3. Matos, A.A., Branco, J.C., Canas Silva, J., Viana Queiroz, M., Pádua, F.: Inquérito epidemiológico de doenças reumáticas numa amostra da população portuguesa (resultados preliminares). Acta Reumatol. Port. 16(1), 98 (1991)
4. National Institute for Health and Clinical Excellence: Rheumatoid arthritis—National clinical guideline for management and treatment in adults. NICE, London (2009)
5. Singh, J.A., Christensen, R., Wells, G.A., et al.: Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Review). Cochrane Database Syst. Rev. (4) (2009). doi: 10.1002/14651858.CD007848.pub2